Cardiovascular Drugs

Learning Objectives

By the end of this page, you should be able to:

• Classify antihypertensive drugs by mechanism and explain how each class lowers blood pressure.
• Describe the Vaughan Williams classification of antiarrhythmic drugs and match each class to its ion-channel target.
• Differentiate the anticoagulant classes (heparins, warfarin, DOACs) by mechanism, monitoring, and reversal.
• Explain how statins, fibrates, and other lipid-lowering agents alter the lipid profile and reduce cardiovascular risk.
• Predict and explain the characteristic side effects of ACE inhibitors, beta-blockers, calcium channel blockers, and statins.
• Apply this knowledge to choose an appropriate drug class for a given clinical scenario (e.g., a diabetic with hypertension, or a post-MI patient).

Quick Answer

Cardiovascular drugs treat disorders of the heart and blood vessels — hypertension, arrhythmias, thrombosis, and dyslipidemia — by acting on four main targets: vascular tone (antihypertensives, vasodilators), cardiac electrical activity (antiarrhythmics), clotting (anticoagulants and antiplatelets), and lipid metabolism (statins and friends). They matter because cardiovascular disease remains the leading cause of death worldwide, and these five drug families — ACE inhibitors, beta-blockers, calcium channel blockers, anticoagulants, and statins — form the backbone of almost every cardiology prescription and exam question you will encounter.

Antihypertensive Drugs

How blood pressure gets lowered

Blood pressure is simply cardiac output multiplied by peripheral resistance (BP = CO × PVR). Every antihypertensive class works by knocking down one of these two variables, either directly or through the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system that regulate them.

ACE inhibitors (lisinopril, enalapril, ramipril) block the enzyme that converts angiotensin I to angiotensin II. Less angiotensin II means less vasoconstriction and less aldosterone-driven sodium/water retention — so both resistance and volume drop. The same enzyme (ACE, also called kininase II) normally breaks down bradykinin; blocking it lets bradykinin accumulate, which is why ACE inhibitors cause a dry cough in roughly 10-20% of patients and, rarely, angioedema. ARBs (losartan, valsartan) block the angiotensin II receptor directly instead of the enzyme, so they give the same hemodynamic benefit without the bradykinin-driven cough — the go-to substitute when a patient can't tolerate an ACE inhibitor.

Beta-blockers (metoprolol, atenolol, propranolol) block beta-1 receptors in the heart, reducing heart rate, contractility, and renin release from the kidney — all of which lower cardiac output and blood pressure over time. Non-selective agents like propranolol also block beta-2 receptors in the bronchi, which is why they're used cautiously (or avoided) in asthmatics.

Calcium channel blockers stop calcium from entering vascular smooth muscle and cardiac cells through L-type channels. Dihydropyridines (amlodipine, nifedipine) act mainly on vascular smooth muscle, causing vasodilation with reflex tachycardia and ankle edema. Non-dihydropyridines (verapamil, diltiazem) act more on the heart itself, slowing AV conduction and reducing heart rate — useful for both hypertension and rate control in arrhythmias, but risky to combine with beta-blockers because both suppress the AV node.

Diuretics lower blood pressure mainly by reducing plasma volume. Thiazides (hydrochlorothiazide) are first-line for most patients; loop diuretics (furosemide) are reserved for volume overload or renal impairment; potassium-sparing agents (spironolactone) block aldosterone and are especially useful in resistant hypertension and heart failure.

Antiarrhythmic Drugs

Antiarrhythmics are organized by the Vaughan Williams classification, which groups drugs by which part of the cardiac action potential they interrupt.

Class	Mechanism	Example	Main Use
I	Sodium channel blockade (slows phase 0 depolarization)	Quinidine (IA), Lidocaine (IB), Flecainide (IC)	Ventricular arrhythmias
II	Beta-blockade (reduces sympathetic drive to the SA/AV node)	Metoprolol, Esmolol	Rate control, post-MI arrhythmia prevention
III	Potassium channel blockade (prolongs repolarization/QT)	Amiodarone, Sotalol	Atrial fibrillation, ventricular tachycardia
IV	Calcium channel blockade (slows AV node conduction)	Verapamil, Diltiazem	Supraventricular tachycardia, rate control in AF

Amiodarone is the drug students most often get wrong: it's classified as Class III, but it actually has properties of all four classes, plus a very long half-life (weeks) and toxicities that show up in exams disproportionately often — pulmonary fibrosis, thyroid dysfunction (both hypo- and hyperthyroidism, because of its iodine content), corneal microdeposits, and blue-grey skin discoloration. Digoxin doesn't fit the Vaughan Williams scheme at all — it increases vagal tone to slow the AV node and is used for rate control in atrial fibrillation, with a narrow therapeutic index that makes toxicity a recurring exam topic (visual halos, arrhythmias, hyperkalemia in acute overdose).

Anticoagulants

Anticoagulants prevent clot formation or propagation, distinct from antiplatelets (aspirin, clopidogrel) which block platelet aggregation.

Unfractionated heparin activates antithrombin III, which then inhibits both thrombin (factor IIa) and factor Xa. It works immediately, is given IV, and is monitored with aPTT — useful because it's fast-acting and reversible with protamine sulfate, making it the choice for acute settings like unstable angina or before procedures.

Low-molecular-weight heparin (enoxaparin) also activates antithrombin III but is more selective for factor Xa than thrombin. It has predictable pharmacokinetics, doesn't need routine monitoring, and can be given subcutaneously — which is why it has largely replaced unfractionated heparin outside the ICU.

Warfarin inhibits vitamin K epoxide reductase, blocking the synthesis of factors II, VII, IX, and X (plus proteins C and S). Because it takes several days to deplete existing clotting factors, it's always started overlapping with heparin ("bridging") and monitored with INR (target 2-3 for most indications). Its many food and drug interactions (vitamin K-rich vegetables, antibiotics, NSAIDs) make it one of the trickiest drugs to manage clinically.

Direct oral anticoagulants (DOACs) — dabigatran (direct thrombin inhibitor) and rivaroxaban/apixaban (direct factor Xa inhibitors) — act directly on a single clotting factor without needing antithrombin. They have predictable dosing, no routine monitoring, and fewer interactions than warfarin, which is why they've become first-line for atrial fibrillation and venous thromboembolism in patients without mechanical heart valves or significant renal impairment.

Lipid-Lowering Drugs

Statins (atorvastatin, simvastatin, rosuvastatin) are the cornerstone of lipid management. They competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Less intracellular cholesterol triggers the liver to upregulate LDL receptors, pulling more LDL out of the blood — this is why statins lower LDL far more than they raise HDL or lower triglycerides. Beyond the numbers, statins also stabilize atherosclerotic plaques and reduce vascular inflammation, which is part of why they cut cardiovascular events even before LDL fully normalizes. The two side effects that show up constantly on exams are myopathy (muscle aches, and rarely rhabdomyolysis with markedly elevated CK) and hepatotoxicity (transaminitis) — both are why liver enzymes and symptoms of muscle pain are monitored.

Other classes fill in the gaps statins don't cover:

• Fibrates (fenofibrate, gemfibrozil) activate PPAR-alpha, primarily lowering triglycerides — the go-to choice when triglycerides are severely elevated.
• Bile acid resins (cholestyramine) bind bile acids in the gut, forcing the liver to convert more cholesterol into new bile acids, which modestly lowers LDL but often causes GI bloating and constipation.
• Ezetimibe blocks intestinal cholesterol absorption (via the NPC1L1 transporter) and is often added to a statin for extra LDL lowering without extra myopathy risk.
• PCSK9 inhibitors (evolocumab, alirocumab) are injectable monoclonal antibodies that prevent LDL receptor degradation, producing dramatic LDL reductions in patients who can't reach goal on statins alone.

Key Terms

Term	Definition
RAAS	Renin-angiotensin-aldosterone system; the hormonal cascade that raises blood pressure via angiotensin II and aldosterone, and the main target of ACE inhibitors and ARBs.
Bradykinin	A vasodilating peptide normally degraded by ACE; its accumulation with ACE inhibitor use causes cough and angioedema.
Vaughan Williams classification	The four-class system (I-IV) that groups antiarrhythmics by the ion channel or receptor they act on.
Antithrombin III	A plasma protein that inactivates thrombin and factor Xa; heparins work by accelerating its activity.
INR	International Normalized Ratio; standardized measure of clotting time used to monitor warfarin therapy.
HMG-CoA reductase	The rate-limiting enzyme in hepatic cholesterol synthesis; the molecular target of statins.
Reflex tachycardia	A compensatory rise in heart rate triggered by baroreceptors sensing a drug-induced drop in blood pressure, seen classically with dihydropyridine calcium channel blockers and direct vasodilators.
Therapeutic index	The ratio between the toxic dose and the effective dose of a drug; narrow for warfarin and digoxin, which is why both need close monitoring.

Common Mistakes

Misconception 1: "ACE inhibitors and ARBs work the same way, so it doesn't matter which one a patient is on." Why it's wrong: Both block the RAAS, but only ACE inhibitors also raise bradykinin levels, because ACE (not the angiotensin receptor) is the enzyme that normally degrades bradykinin. Correct explanation: ARBs give equivalent blood pressure and renal protection benefits without the bradykinin-mediated cough or angioedema risk, which is exactly why they're substituted in patients who can't tolerate an ACE inhibitor — they are not interchangeable in mechanism, just in net effect.

Misconception 2: "Amiodarone is a Class III antiarrhythmic, full stop." Why it's wrong: Students memorize the Vaughan Williams box and stop there, but amiodarone actually blocks sodium channels (Class I), has beta-blocking activity (Class II), blocks potassium channels (Class III), and blocks calcium channels (Class IV) all at once. Correct explanation: Its broad-spectrum activity is exactly why it's effective against such a wide range of arrhythmias, and also why it carries such an unusually broad toxicity profile (thyroid, lung, liver, skin, cornea) compared to more selective antiarrhythmics.

Misconception 3: "Warfarin and heparin do the same job, so either can be used interchangeably in an emergency." Why it's wrong: Warfarin blocks the synthesis of new clotting factors, so it takes days to become effective (and can even transiently increase clot risk early on, by depleting protein C faster than the pro-clotting factors). Correct explanation: In an acute clotting emergency you need immediate anticoagulation, so heparin (which directly inhibits already-circulating thrombin and factor Xa via antithrombin) is used first and bridged with warfarin until the INR is therapeutic — this bridging is a frequently tested clinical point.

Comparison and Connections

Drug Class	Primary Target	Onset	Key Monitoring	Classic Side Effect
ACE inhibitors	Angiotensin-converting enzyme	Hours-days	Potassium, creatinine	Dry cough, angioedema, hyperkalemia
Beta-blockers	Beta-1 adrenergic receptors	Hours	Heart rate, blood pressure	Bradycardia, fatigue, bronchospasm (non-selective)
Dihydropyridine CCBs	L-type calcium channels (vascular)	Hours	Blood pressure, edema	Ankle edema, flushing, reflex tachycardia
Unfractionated heparin	Antithrombin III (thrombin + Xa)	Minutes (IV)	aPTT	Heparin-induced thrombocytopenia (HIT)
Warfarin	Vitamin K epoxide reductase	Days	INR	Bleeding, teratogenicity
DOACs	Single factor (IIa or Xa)	Hours	Usually none routine	Bleeding, limited reversal options
Statins	HMG-CoA reductase	Weeks (LDL effect)	LFTs, CK if symptomatic	Myopathy, transaminitis

Practice Questions

Recall

1. Which enzyme do ACE inhibitors block, and what two downstream hormones does this reduce? Answer guidance: They block angiotensin-converting enzyme, reducing the formation of angiotensin II and, consequently, aldosterone secretion.
2. Name one drug from each Vaughan Williams class (I-IV). Answer guidance: Class I — quinidine/lidocaine/flecainide; Class II — metoprolol; Class III — amiodarone/sotalol; Class IV — verapamil/diltiazem.

Understanding 3. Explain why ACE inhibitors cause a dry cough but ARBs typically do not. Answer guidance: ACE also degrades bradykinin; blocking ACE lets bradykinin accumulate and irritate the airway. ARBs act at the angiotensin receptor, leaving bradykinin metabolism untouched. 4. Why does warfarin require bridging with heparin when starting anticoagulation for a new clot? Answer guidance: Warfarin only stops synthesis of new clotting factors; existing factors (with half-lives up to 60+ hours for factor II) remain active for days, and protein C (anticoagulant) falls faster than the pro-clotting factors, creating a transient hypercoagulable window — heparin covers this gap.

Application 5. A 55-year-old with hypertension and type 2 diabetes is starting antihypertensive therapy. Which class is preferred first-line, and why? Answer guidance: ACE inhibitors (or ARBs) are preferred because they also reduce intraglomerular pressure and proteinuria, providing renoprotection in diabetic nephropathy beyond their blood pressure effect. 6. A patient on simvastatin reports new, severe muscle pain with dark urine. What is happening and what should be checked? Answer guidance: Suspect statin-induced myopathy progressing to rhabdomyolysis; check creatine kinase (CK) and renal function, and hold the statin.

Analysis 7. Compare why verapamil (a Class IV antiarrhythmic) should not be combined with a beta-blocker, even though both are used for rate control. Answer guidance: Both suppress AV nodal conduction and depress cardiac contractility through different mechanisms (calcium vs. beta-adrenergic blockade); combined, they risk severe bradycardia, heart block, or cardiogenic shock. 8. A patient with atrial fibrillation could be anticoagulated with warfarin or a DOAC. Analyze the trade-offs between the two options. Answer guidance: Warfarin is cheaper, has a reversal agent (vitamin K, prothrombin complex concentrate) and long track record, but needs INR monitoring and has many interactions; DOACs need no routine monitoring and have fewer interactions, but are costlier, have limited reversal options in some cases, and are contraindicated with mechanical heart valves or significant renal impairment.

FAQ

Q1: Why do ACE inhibitors and ARBs both require monitoring potassium levels? Both reduce aldosterone (directly for ACE inhibitors, downstream for ARBs), and aldosterone is what normally drives potassium excretion in the kidney — so blocking the RAAS predisposes patients to hyperkalemia, especially when combined with potassium-sparing diuretics.

Q2: Why is amiodarone used despite its long list of toxicities? It's remarkably effective against a broad range of both atrial and ventricular arrhythmias where other agents fail, and for life-threatening arrhythmias the short-term benefit usually outweighs the risk of toxicities that mainly develop with chronic use.

Q3: Why do dihydropyridine calcium channel blockers cause ankle edema? They dilate arterioles more than venules, so more fluid gets pushed out of the capillaries into the interstitial space than gets drained back — this is a hemodynamic effect, not fluid retention, which is why diuretics don't fix it well.

Q4: If statins lower LDL so effectively, why do we still need fibrates or ezetimibe? Statins are least effective at lowering triglycerides, which is where fibrates excel, and some patients can't reach LDL goals on a statin alone or can't tolerate a higher statin dose — ezetimibe adds LDL lowering through a completely separate mechanism (blocking intestinal absorption) without extra myopathy risk.

Q5: Why can't heparin and warfarin be monitored with the same lab test? They act on different parts of the coagulation cascade — heparin potentiates antithrombin's inhibition of thrombin and factor Xa (tracked by aPTT), while warfarin blocks synthesis of vitamin K-dependent factors, best reflected by the extrinsic pathway-sensitive prothrombin time, standardized as the INR.

Quick Revision

• BP = Cardiac Output × Peripheral Resistance; every antihypertensive lowers one or both.
• ACE inhibitors ("-pril") block angiotensin II formation and raise bradykinin → dry cough, angioedema, hyperkalemia.
• ARBs ("-sartan") block the angiotensin II receptor directly — same benefits, no cough.
• Beta-blockers cut heart rate, contractility, and renin release; avoid combining with verapamil/diltiazem (AV block risk).
• Dihydropyridine CCBs (amlodipine) → vasodilation, reflex tachycardia, ankle edema; non-dihydropyridines (verapamil, diltiazem) → AV node suppression, rate control.
• Vaughan Williams: I = Na⁺ channel blockers, II = beta-blockers, III = K⁺ channel blockers, IV = Ca²⁺ channel blockers; amiodarone spans all four.
• Digoxin is not in the Vaughan Williams system; narrow therapeutic index, watch for visual halos and hyperkalemia in toxicity.
• Heparin/LMWH act fast via antithrombin III (monitor aPTT); warfarin blocks vitamin K epoxide reductase and takes days (monitor INR); DOACs hit a single factor directly with minimal monitoring.
• Always bridge warfarin with heparin when starting anticoagulation acutely.
• Statins inhibit HMG-CoA reductase → less cholesterol synthesis → more hepatic LDL receptor uptake; watch for myopathy and transaminitis.
• Fibrates target triglycerides; ezetimibe blocks intestinal cholesterol absorption; PCSK9 inhibitors give the largest LDL drops for refractory cases.
• ACE inhibitors/ARBs are preferred first-line in diabetic hypertensive patients for their renoprotective effect.

Related Topics

Prerequisites

• Basic cardiac physiology (cardiac output, blood pressure regulation)
• Cardiac action potential phases and ion channel physiology
• The coagulation cascade

Related Topics

• Antiplatelet drugs (aspirin, clopidogrel) and their distinction from anticoagulants
• Diuretic pharmacology in heart failure
• Autonomic nervous system pharmacology (adrenergic and cholinergic receptors)

Next Topics

• Drugs used in heart failure (inotropes, neurohormonal antagonists)
• Anti-anginal drugs and their overlap with antihypertensives
• Clinical pharmacology of anticoagulant reversal and perioperative management